Biomerica: Biomerica Secures Three Key International Patents for inFoods Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn's Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+)The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent TreatyIRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease ("GERD"), Crohn's Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization ("EPO"), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO.Prevalence and Market Potential in EuropeGERD, Crohn's Disease and Ulcerative Colitis represent significant worldwide healthcare challenges across Europe.GERD: The GERD treatment market in Europe exceeds $4 billion annually. Studies indicate that 8.8% to 25.9% of Europeans experience GERD symptoms weekly (gut.bmj.com), with lifetime risk ranging between 20% and 30%. Recent research has linked long-term use of proton pump inhibitors ("PPIs")-a common GERD treatment-to serious health risks, including Alzheimer's disease and kidney damage, underscoring the need for safer, innovative solutions like inFoods®.Crohn's Disease: The market for Crohn's Disease treatments in Europe is estimated at $2.5 billion annually (gminsights.com). This chronic inflammatory condition requires new approaches to improve patient outcomes and reduce healthcare costs.Ulcerative Colitis: The European market size of $1.5 billion in 2023 is projected to surpass $1.9 billion by 2028 according to Market Data Forecasts.These recent notices of allowance and issuance of patents are a significant milestone in Biomerica's mission to enhance patient care through personalized medical solutions. The Company is currently marketing an inFoods® Technology test to treat IBS sufferers, which is already covered by 15 different patents globally. The issuance of patents in these additional disease states opens the door for Biomerica to complete development of inFoods therapeutic products to treat patients within this broader spectrum of gastrointestinal diseases.inFoods®: A Personalized and Safer Approach to GI CareBiomerica's inFoods® Technology is a diagnostic-guided platform that identifies specific foods in each patient that trigger worsening symptoms in GERD, Crohn's Disease, and Ulcerative Colitis. This allows healthcare providers to create personalized dietary plans, addressing the root cause of ...Full story available on Benzinga.com